Blog

Please log into the following website and complete the assessment titled “ATI RN Pharmacology Online Practice 2023 A” www.atitesting.com I have completed the ATI RN Pharmacology Practice 2023 A by accessing this “quiz” through HonorLock.  RN Pharmacology Online Practice 2023 A – is open & available for completion.  ***Handwritten remediation & Individual Performance Profile submission due by Monday November 24th at 11:59pm. (See ATI Module for submission details.)

Please log into the following website and complete the assessment titled “ATI RN Pharmacology Online Practice 2023 B” www.atitesting.com I have completed the ATI RN Pharmacology Practice 2023 B by accessing this “quiz” through HonorLock.  RN Pharmacology Online Practice 2023 B – is open & available for completion.  ***Handwritten remediation & Individual Performance Profile submission due by Monday November 24th at 11:59pm. (See ATI Module for submission details.)

Describe the relationship between preload, afterload, and contractility. Include discussion of the Frank-Starling law as it relates to these relationships.

Cirrhosis 1. Background Definition: End-stage fibrosis and nodular regeneration of the liver resulting from chronic liver injury, leading to distortion of hepatic architecture, portal hypertension, and hepatic insufficiency. Pathophysiology: Chronic hepatocellular injury (inflammation, necrosis) → fibrosis → nodular regeneration → disruption of hepatic blood flow and function. Portal hypertension develops from increased intrahepatic resistance. Etiologies: Chronic viral hepatitis: HBV, HCV (most common worldwide). Alcohol-associated liver disease. Nonalcoholic steatohepatitis (NASH). Autoimmune hepatitis, hemochromatosis, Wilson disease, α1-antitrypsin deficiency, biliary disease. Epidemiology: A leading cause of death worldwide. Increasing prevalence due to metabolic syndrome and NAFLD/NASH. 2. History Early (compensated): Often asymptomatic or mild nonspecific fatigue, weakness, or anorexia. Decompensated (advanced): Jaundice Ascites Peripheral edema Hepatic encephalopathy (confusion, asterixis) Gastrointestinal bleeding from esophageal or gastric varices Easy bruising or prolonged bleeding (coagulopathy) Other features: Pruritus (especially in cholestatic causes) Dark urine / pale stools Sexual dysfunction, gynecomastia, menstrual irregularities (endocrine effects). 3. Exam Findings General: Jaundice, muscle wasting, fatigue. Skin: Spider angiomas, palmar erythema, bruising, jaundice. Abdomen: Hepatomegaly (early) → small, shrunken liver (late). Ascites, shifting dullness. Splenomegaly (portal hypertension). Caput medusae (distended abdominal veins). Neurologic: Asterixis, confusion (hepatic encephalopathy). Endocrine: Gynecomastia, testicular atrophy. 4. Making the Diagnosis A. Laboratory Findings LFT pattern: AST > ALT (esp. alcoholic), elevated bilirubin, low albumin, prolonged PT/INR. Other labs: Thrombocytopenia (splenic sequestration), hyponatremia. Confirmatory: Elevated serum fibrosis markers or biopsy (definitive but not always required). B. Imaging Ultrasound: First-line; shows nodular liver, splenomegaly, ascites. Elastography: Noninvasive measurement of liver stiffness. CT/MRI: Evaluate for nodularity, portal hypertension, HCC. C. Assessing Severity Child-Pugh score: Grades liver function (bilirubin, albumin, INR, ascites, encephalopathy). MELD score: Predicts mortality and determines liver transplant priority. D. Complications to Screen For Hepatocellular carcinoma (HCC): Ultrasound ± AFP every 6 months. Varices: Screening endoscopy. Hepatorenal syndrome spontaneous bacterial peritonitis (SBP) (ascites with >250 PMNs/µL, fever, abdominal pain) 5. Management A. General Management Treat underlying cause: Abstain from alcohol. Antivirals for HBV/HCV. Weight loss for NASH. Chelation (Wilson disease) or phlebotomy (hemochromatosis). Avoid hepatotoxins (NSAIDs, acetaminophen >2g/day). Vaccinations: HAV, HBV, influenza, pneumococcal. B. Management of Complications Complication Management Ascites Sodium restriction, diuretics (spironolactone ± furosemide), paracentesis, avoid NSAIDs Spontaneous Bacterial Peritonitis (SBP) Empiric cefotaxime; prophylaxis with norfloxacin or TMP-SMX Variceal Bleeding Octreotide, endoscopic band ligation, nonselective beta-blockers (propranolol/nadolol) for prevention Hepatic Encephalopathy Lactulose ± rifaximin, avoid sedatives Hepatorenal Syndrome Albumin, vasoconstrictors (midodrine/octreotide), treat precipitating factors C. Definitive Therapy Liver transplantation: Only curative option for end-stage disease. Indicated by MELD score ≥15 or recurrent decompensation.   Question A 58-year-old man with a history of alcohol-associated cirrhosis presents with increasing abdominal distension and confusion over the past week. His temperature is 100.6°F (38.1°C), blood pressure 102/64 mm Hg, and pulse 96/min. On examination, he has jaundice, ascites with shifting dullness, and mild asterixis. Paracentesis reveals: WBC count: 420 cells/µL (80% neutrophils) Protein: 0.8 g/dL Culture: Escherichia coli Which of the following is the most likely complication responsible for this presentation?

Achalasia 1. Background Definition: Primary esophageal motility disorder characterized by impaired relaxation of the lower esophageal sphincter (LES) and loss of peristalsis in the distal esophagus. Pathophysiology: Degeneration of inhibitory ganglion cells in the myenteric (Auerbach’s) plexus leads to unopposed excitatory stimulation, causing LES hypertonicity and functional obstruction. Epidemiology: Rare (~1 in 100,000 annually); usually presents between ages 25–60; affects men and women equally. Etiology: Mostly idiopathic; secondary (pseudoachalasia) may result from malignancy (e.g., gastric cardia adenocarcinoma) or Chagas disease. 2. History Symptoms: Progressive dysphagia to both solids and liquids (unlike mechanical obstruction). Regurgitation of undigested food, especially at night. Chest pain or pressure after eating. Weight loss from poor intake. Possible heartburn-like symptoms unresponsive to PPIs. Duration: Typically develops gradually over months to years. Risk factors: None established; may have association with autoimmune or viral mechanisms. 3. Exam Findings Often unremarkable; may note mild weight loss or signs of malnutrition. Pulmonary findings (e.g., wheezing, cough) may occur from aspiration of regurgitated food. 4. Making the Diagnosis Gold standard: Esophageal manometry — shows absent peristalsis and incomplete LES relaxation (definitive diagnostic test). Commonly used/initial tests: Barium swallow (esophagram): “Bird’s beak” tapering at LES with proximal esophageal dilation (often first clue). Endoscopy (EGD): Performed to rule out malignancy (pseudoachalasia) or secondary causes; may show retained food or saliva. Note: All three tests are often used sequentially — barium swallow suggests diagnosis, manometry confirms, and endoscopy excludes malignancy. 5. Management A. Lifestyle / Supportive Eat slowly, chew thoroughly, and elevate head of bed. Avoid eating close to bedtime. B. Medications (temporary or bridge therapy) Nitrates or calcium channel blockers (e.g., nifedipine) lower LES pressure but have limited long-term benefit. Botulinum toxin injection into LES provides short-term relief (useful for nonsurgical candidates). C. Definitive Procedures Pneumatic dilation: Endoscopic balloon disruption of LES fibers; effective but may require repeat treatments. Heller myotomy (laparoscopic): Surgical division of LES muscles; often combined with partial fundoplication to prevent reflux. Peroral endoscopic myotomy (POEM): Minimally invasive endoscopic alternative to Heller myotomy with similar outcomes. Question A 38-year-old woman reports a 6-month history of progressive difficulty swallowing both solids and liquids. She also notes occasional regurgitation of undigested food and mild, unintentional weight loss. She has no heartburn relief with proton pump inhibitors. A barium swallow shows a dilated esophagus tapering to a narrow “bird’s beak” at the gastroesophageal junction. Which of the following is the most appropriate next diagnostic step to confirm the diagnosis?

Infectious Diarrhea 1. Background Definition: Diarrhea caused by infection of the GI tract with bacteria, viruses, or parasites, leading to increased water loss through inflammation, secretion, or decreased absorption. Pathophysiology: Noninvasive (secretory/toxin-mediated): Acts on intestinal mucosa without invasion → watery diarrhea (no blood or fecal WBCs). Invasive (inflammatory): Pathogen invades mucosa → bloody or mucoid diarrhea, fever, and fecal leukocytes. Common etiologies: Bacterial: E. coli (ETEC, EHEC), Salmonella, Shigella, Campylobacter, Vibrio cholerae, Clostridioides difficile. Viral: Norovirus, Rotavirus, Adenovirus. Parasitic: Giardia lamblia, Entamoeba histolytica, Cryptosporidium. Epidemiology: Common worldwide; spread via contaminated food, water, or person-to-person contact; travelers and immunocompromised at higher risk. 2. History Symptoms: Diarrhea (watery or bloody), abdominal cramping, nausea, vomiting, fever. Duration: Acute (14 days). Risk factors: Recent travel, antibiotic use, undercooked meats, unpasteurized dairy, daycare exposure, contaminated water, immunosuppression. Clues to etiology: Watery, no blood: Viral, ETEC, cholera, Giardia. Bloody, fever: Shigella, Salmonella, Campylobacter, EHEC, Entamoeba histolytica. Post-antibiotic: C. difficile. 3. Exam Findings General: May show dehydration (dry mucous membranes, tachycardia, hypotension). Abdomen: Mild tenderness; peritoneal signs suggest complication (toxic megacolon, perforation). Other clues: Weight loss (parasite), jaundice (hepatitis A coinfection), neurologic sequelae (EHEC → HUS). 4. Making the Diagnosis Initial step: Clinical diagnosis based on history and exposure. Gold standard: Stool culture and/or multiplex PCR panel to identify bacterial or parasitic pathogens. Common tests: Stool for ova and parasites (O&P): if >7 days or travel history. C. difficile toxin or PCR: if recent antibiotic or healthcare exposure. Fecal leukocytes or lactoferrin: suggest invasive etiology. No testing needed for most mild viral cases. 5. Management A. Supportive (Mainstay) Oral rehydration and electrolyte replacement are primary therapy. IV fluids for severe dehydration. Diet: Continue light meals; avoid lactose and high-fat foods. B. Antibiotic Therapy (Targeted) Empiric antibiotics (select cases): Severe traveler’s diarrhea: azithromycin or fluoroquinolone. C. difficile: oral vancomycin or fidaxomicin. Giardia: tinidazol or metronidazole. Shigella/Campylobacter: azithromycin if severe. Avoid antibiotics in EHEC (O157:H7) — risk of hemolytic uremic syndrome (HUS). C. Prevention Safe food and water practices when traveling. Hand hygiene, vaccination (rotavirus, cholera in endemic regions).   Question A 26-year-old woman returns from a week-long trip to out of the country and presents with 3 days of profuse, watery diarrhea and mild abdominal cramping. She denies blood in the stool, fever, or vomiting. Physical examination shows dry mucous membranes and mild tachycardia. Which of the following is the most appropriate initial management for this patient?

Zollinger–Ellison Syndrome (ZES) 1. Background Definition: A disorder caused by a gastrin-secreting neuroendocrine tumor (gastrinoma) that leads to excess gastric acid production and refractory peptic ulcer disease. Pathophysiology: Gastrinomas (often in the pancreas, duodenum, or lymph nodes) cause marked acid hypersecretion, resulting in multiple or recurrent ulcers and diarrhea. Acid inactivates pancreatic enzymes → malabsorption and steatorrhea. Epidemiology: Rare; typically diagnosed in adults 30–60 years. 20–25% associated with Multiple Endocrine Neoplasia type 1 (MEN1). Complications: Severe ulceration, perforation, GI bleeding, strictures, or malignancy (⅔ of gastrinomas are malignant). 2. History Symptoms: Recurrent or multiple peptic ulcers, often in distal duodenum or jejunum. Epigastric pain, heartburn, diarrhea, or steatorrhea. Ulcers refractory to standard therapy or recurring after surgery. Clues suggesting ZES: Ulcers without NSAID or H. pylori exposure. Prominent diarrhea or fat malabsorption. Family history of endocrine tumors (MEN1). 3. Exam Findings Nonspecific abdominal tenderness; often normal. Signs of MEN1 (if present): Hyperparathyroidism (kidney stones, bone pain). Pituitary adenoma features. 4. Making the Diagnosis Screening test: Fasting serum gastrin level >10 times the upper limit of normal with gastric pH

Gastroesophageal Reflux Disease (GERD) 1. Background Anatomy: The lower esophageal sphincter (LES) forms a high-pressure barrier between the esophagus and stomach. Supportive structures include the diaphragmatic crura and angle of His, which help prevent reflux. Pathophysiology: GERD results from transient LES relaxation or incompetence, allowing gastric acid and pepsin to reflux into the esophagus. Chronic exposure leads to mucosal inflammation, erosive esophagitis, stricture, or Barrett’s esophagus. Epidemiology: Prevalence approaches 20% of adults in Western countries; incidence increases with age, obesity, and pregnancy. Genetics: Familial clustering observed; multifactorial inheritance related to obesity, hiatal hernia, and visceral adiposity. Common associated conditions: Hiatal hernia, delayed gastric emptying, scleroderma, obesity, pregnancy, and medications reducing LES tone. 2. History Typical symptoms: Heartburn (pyrosis), regurgitation, sour or bitter taste, symptoms worse after meals or lying down, improved by antacids. Atypical manifestations: Chronic cough, laryngitis, asthma exacerbation, noncardiac chest pain, or dental enamel erosion. Risk factors: Obesity, pregnancy, hiatal hernia Smoking, alcohol, caffeine, chocolate, peppermint, fatty meals Medications: calcium channel blockers, nitrates, anticholinergics, theophylline, estrogen, progesterone Connective tissue disease (scleroderma) 3. Exam Findings Uncomplicated GERD: Often normal physical exam. Possible findings: Mild epigastric tenderness Pharyngeal erythema or dental enamel loss (extra-esophageal reflux) Weight loss, anemia, or heme-positive stool suggesting complications such as Barrett’s, ulceration, or malignancy. 4. Making the Diagnosis Gold standard: 24-hour ambulatory esophageal pH monitoring (with or without impedance) is the gold standard for confirming abnormal acid exposure. However, this test is not routinely required in typical presentations; it is reserved for: Persistent or atypical symptoms despite PPI therapy Diagnostic uncertainty Preoperative evaluation before antireflux surgery Typical clinical approach: Empiric PPI trial for 4–8 weeks serves as both diagnostic and therapeutic in patients with classic symptoms and no alarm features. Endoscopy (EGD): Indicated for alarm symptoms (dysphagia, odynophagia, weight loss, GI bleeding, anemia, vomiting), failure of empiric therapy, or long-standing GERD (>5 years) to evaluate for Barrett’s esophagus. Esophageal manometry: Used when motility disorders such as achalasia are suspected or before surgical intervention. Imaging: Barium swallow may demonstrate reflux or hiatal hernia but is not diagnostic. 5. Management A. Lifestyle Modifications Weight loss in overweight/obese patients (most effective non-drug intervention). Elevate head of bed 6–8 inches, avoid lying down within 3 hours after meals (best for reducing reflux). Avoid dietary triggers (fatty/spicy foods, chocolate, caffeine, alcohol, and reducing acidity). Stop smoking and limit alcohol. Smaller, more frequent meals; avoid late-night eating (effective for reducing reflux). Review and adjust medications that lower LES tone when feasible. B. Medication Therapy Step-up approach: Begin with H2 receptor antagonist → escalate to PPI if persistent symptoms. Step-down approach: Start with PPI, then taper to lowest effective dose. PPIs (omeprazole, esomeprazole, pantoprazole): First-line for frequent or erosive GERD; initial course 4–8 weeks. H2 receptor antagonists (famotidine): For mild or intermittent symptoms. Antacids/alginates: Immediate symptomatic relief; short-acting. Prokinetics (metoclopramide): Consider only for documented motility disorder; limited use due to adverse effects. C. Procedures and Surgery Indications: Refractory GERD, medication intolerance, or complications (e.g., severe regurgitation, Barrett’s with dysplasia). Nissen fundoplication: Standard surgical correction—tightens LES by wrapping gastric fundus. LINX magnetic sphincter augmentation: Minimally invasive alternative using magnetic beads to reinforce LES tone. Endoscopic therapies: Radiofrequency ablation or plication; less common and variable in long-term success.   Question A 42-year-old woman reports a 6-month history of heartburn and regurgitation that occur several times per week, especially after large meals or when lying down. She takes no regular medications. Physical examination is normal. Which of the following lifestyle modifications is most likely to provide the greatest improvement in her symptoms?    

Hemorrhoids 1. Background Definition: Dilated and symptomatic venous cushions of the hemorrhoidal plexus in the anal canal. Anatomy: Internal hemorrhoids: Above the dentate line; covered by columnar mucosa; visceral innervation → painless. External hemorrhoids: Below the dentate line; covered by squamous epithelium; somatic innervation → painful when thrombosed. Pathophysiology: Increased venous pressure from straining, constipation, prolonged sitting, pregnancy, portal hypertension, or obesity causes engorgement and prolapse of venous plexus. Epidemiology: Common in adults 45–65 years; prevalence rises with age and constipation. 2. History Internal hemorrhoids: Painless bright red rectal bleeding (on toilet paper or dripping after defecation). Mucosal prolapse or soiling in advanced grades. External hemorrhoids: Painful perianal lump (thrombosis) with acute onset after straining or prolonged sitting. May have pruritus or swelling but typically no bleeding unless ulcerated. Risk factors: Chronic constipation, prolonged sitting, low-fiber diet, pregnancy, portal hypertension, or frequent heavy lifting. 3. Exam Findings Inspection: External: Visible bluish perianal mass if thrombosed. Internal: Not always visible unless prolapsed (use anoscopy). Digital rectal exam: May reveal soft compressible masses or exclude other causes (fissure, abscess, tumor). Anoscopy: Confirms diagnosis and grades internal hemorrhoids: Grade I: No prolapse, bleeds only Grade II: Prolapse with straining, reduces spontaneously Grade III: Prolapse requires manual reduction Grade IV: Irreducible, may thrombose or ulcerate 4. Making the Diagnosis Clinical diagnosis: Based on history and physical exam (inspection, DRE, anoscopy). Exclude other causes of bleeding: Colonoscopy indicated in: Age ≥45 or risk factors for colorectal cancer Iron-deficiency anemia or melena Atypical bleeding (dark stool, mixed blood, systemic symptoms) Laboratory: CBC if chronic bleeding suspected. 5. Management A. Conservative (First-line for most) Dietary fiber supplementation and increased fluids. Avoid prolonged straining; use stool softeners (docusate). Topical therapies: Witch hazel, hydrocortisone, or anesthetic creams for short-term relief. Sitz baths for comfort. B. Office Procedures (Persistent Grade I–III) Rubber band ligation (most effective for internal hemorrhoids). Sclerotherapy or infrared coagulation if not surgical candidates. C. Surgical Management Excisional hemorrhoidectomy: For large Grade III–IV internal hemorrhoids or recurrent thrombosed external hemorrhoids. Thrombosed external hemorrhoid: Excision within 72 hours provides rapid pain relief. D. Prevention High-fiber diet, hydration, prompt defecation, and avoidance of prolonged sitting or straining.   Question A 42-year-old man presents with severe anal pain that began suddenly after straining during a bowel movement this morning. He reports mild swelling but no rectal bleeding. Physical examination reveals a tender, bluish perianal nodule below the dentate line. Which of the following is the most appropriate management?

Celiac Disease (Gluten-Sensitive Enteropathy) 1. Background Definition: An autoimmune-mediated intestinal disorder triggered by dietary gluten (wheat, barley, rye) in genetically susceptible individuals. Pathophysiology: Ingestion of gluten → immune response against tissue transglutaminase (tTG) → villous atrophy and crypt hyperplasia in the small intestine → malabsorption. Genetics: Strongly associated with HLA-DQ2 and HLA-DQ8 alleles. Epidemiology: Affects ~1% of the population; higher prevalence in Northern European ancestry and patients with autoimmune diseases (type 1 diabetes, autoimmune thyroiditis). Complications: Malnutrition, iron-deficiency anemia, osteoporosis, infertility, dermatitis herpetiformis, and increased risk of intestinal T-cell lymphoma. 2. History Symptoms (classic form): Chronic diarrhea, steatorrhea, weight loss, abdominal bloating, and fatigue. Atypical/non-GI manifestations: Iron-deficiency anemia, osteoporosis, neuropathy, short stature, delayed puberty, infertility. Dermatologic: Dermatitis herpetiformis — pruritic papulovesicular rash on extensor surfaces. Onset: May appear in childhood or adulthood; often improves when gluten is avoided. Risk factors: Family history, autoimmune diseases, selective IgA deficiency. 3. Exam Findings May be normal in mild cases. Signs of malabsorption: pallor (anemia), glossitis, muscle wasting, or peripheral edema (hypoproteinemia). Rash consistent with dermatitis herpetiformis (elbows, knees, buttocks). 4. Making the Diagnosis Initial test: Serologic testing — tissue transglutaminase IgA (tTG-IgA) and total IgA (to rule out IgA deficiency). Confirmatory test (gold standard): Small bowel biopsy via upper endoscopy showing villous atrophy, crypt hyperplasia, and intraepithelial lymphocytosis. If IgA deficient: Use IgG-based tests (deamidated gliadin peptide IgG or tTG-IgG). HLA typing (DQ2/DQ8): Negative result effectively rules out celiac disease (useful if diagnosis uncertain). Note: Patients must be consuming gluten before testing to avoid false negatives. 5. Management A. Dietary Strict lifelong gluten-free diet (avoid wheat, barley, rye). Nutritional counseling and monitoring for deficiencies (iron, folate, B12, vitamin D, calcium). B. Medical Dermatitis herpetiformis: Dapsone for symptomatic relief, plus gluten-free diet. Treat associated deficiencies (iron, folate, vitamin D, calcium). C. Monitoring Follow-up tTG-IgA titers to assess dietary adherence. Bone density screening (osteoporosis risk). Rare refractory cases may require corticosteroids or immunosuppressants.   Question A 29-year-old woman with chronic diarrhea, bloating, and weight loss undergoes upper endoscopy after positive celiac serology. Duodenal biopsies are obtained. Which of the following histologic findings is most characteristic of this patient’s disease?